Skip to content
type1.science
Phase 1RecruitingNCT07528105

Allogeneic CD7-targeted CAR-T for T1D

Shanghai Zhongshan early-phase study of allogeneic CD7-targeted CAR-T cells in adults with type 1 diabetes, measuring safety, cellular kinetics and C-peptide changes.

Primary endpoints

  • Dose-limiting toxicities and adverse events
  • Change from baseline in 4-hour MMTT C-peptide AUC

Results so far

No results posted yet.